Product Name:4-Phthalimidobutyraldehyde

IUPAC Name:4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butanal

CAS:3598-60-5
Molecular Formula:C12H11NO3
Purity:95%
Catalog Number:CM193099
Molecular Weight:217.22

Packing Unit Available Stock Price($) Quantity
CM193099-250mg in stock ŮƚŌ
CM193099-1g in stock ƈľƿ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:3598-60-5
Molecular Formula:C12H11NO3
Melting Point:-
Smiles Code:O=CCCCN1C(=O)C2=C(C=CC=C2)C1=O
Density:
Catalog Number:CM193099
Molecular Weight:217.22
Boiling Point:373.9°C at 760 mmHg
MDL No:MFCD00454178
Storage:Store at 2-8°C.

Category Infos

Column Infos

Mavorixafor
X4 Pharmaceuticals’ lead product candidate, Mavorixafor (X4P-001) has reached a significant milestone with the submission of a New Drug Application (NDA) to the U.S. FDA for the treatment of WHIM Syndrome on September 5. This marks an important step forward in the regulatory approval process for Mavorixafor and highlights its potential as a promising therapy for patients with WHIM Syndrome.
WHIM syndrome was named after four symptoms: Warts, Hypogammaglobulinemia, Infections, Myelokathexis. WHIM syndrome is a rare and difficult-to-diagnose primary immunodeficiency in which the body’s immune system does not function properly and has trouble fighting infections, especially respiratory, ear, and skin infections.
Mavorixafor is an investigational small-molecule CXCR4 antagonist. It allosterically blocks the overstimulation of the CXCL12/CXCR4 pathway, having the potential to improve immune cell trafficking and immunosurveillance. Mavorixafor was designated orphan drug status by both the U.S. and the EU, and previously granted Fast Track Designation and Breakthrough Therapy Designation by the FDA.

Related Products